Sex Hormone-Based Models Outperform Conventional Scores for Metabolic Dysfunction-Associated Steatotic Liver Disease Screening: A Sex-Specific Analysis in Type 2 Diabetes

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among patients with Type 2 diabetes mellitus (T2DM). Although various noninvasive assessment tools for MASLD are currently available, few have been specifically validated in T2DM populations. Furthermore, the role of sex hormones in MASLD and their potential influence on cardiovascular and renal outcomes remain incompletely understood.